-transparent.png){kind=logo}
The discovery that a series of N,N-dialkyl-N'-arylureas were inhibitors of the ACAT enzyme has led to a structure-activity study involving the systematic modification of three sites of the urea backbone. This study culminated in the selection of N'-(2,4-dimethylphenyl)-N-benzyl-N-n-butylurea (115) for more extensive biological evaluation. ACAT inhibitors are seen as potentially beneficial agents against hypercholesterolemia and atherosclerosis.
Related Publications
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
April 1962,
The American journal of clinical nutrition,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
March 1964,
American heart journal,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
October 1983,
Journal of medicinal chemistry,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
October 1983,
Journal of medicinal chemistry,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
October 1983,
Journal of medicinal chemistry,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
April 1997,
Bioorganic & medicinal chemistry,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
April 1972,
Journal of pharmaceutical sciences,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
January 2015,
Evidence-based complementary and alternative medicine : eCAM,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
June 2014,
Bioorganic chemistry,
V G DeVries, and
J D Bloom, and
M D Dutia, and
A S Katocs, and
E E Largis
October 1993,
Journal of medicinal chemistry,
